Search research articles
Contact Us
Filters
Showing results (1-10 of 146) with videos related to
Page
of 15
Sort By:
Annals of Clinical and Translational Neurology
|
September 18, 2020
Frequent self-assessments in ALS Clinical Trials: worthwhile or an unnecessary burden for patients?
Ruben P A van Eijk
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
October 31, 2019
The rise of innovative clinical trial designs: what's in it for amyotrophic lateral sclerosis?
Ruben P A van Eijk, Angela Genge
Neurology
|
January 24, 2025
Author Response: Trial Participation in Neurodegenerative Diseases: Barriers and Facilitators: A Systematic Review and Meta-Analysis
Daphne N Weemering, Ruben P A van Eijk
Neurology
|
January 24, 2025
Author Response: Trial Participation in Neurodegenerative Diseases: Barriers and Facilitators: A Systematic Review and Meta-Analysis
Daphne N Weemering, Ruben P A van Eijk
Neurology
|
January 24, 2016
Comment: Plateaus and reversals in ALS disease course or limitations of trial design?
Ruben P A van Eijk, Leonard H van den Berg
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
October 12, 2019
In pursuit of the normal progressor: the holy grail for ALS clinical trial design?
Ruben P A van Eijk, Leonard H van Den Berg
Brain : a Journal of Neurology
|
December 10, 2024
Rethinking phase 2 trials in amyotrophic lateral sclerosis
Michael Benatar, Christopher McDermott, Martin R Turner, et al.
Brain : a Journal of Neurology
|
February 5, 2025
Reply: Overstating harms can have consequences
Michael Benatar, Christopher McDermott, Martin R Turner, et al.
Neurology
|
June 14, 2024
Cultivating Patient Preferences in ALS Clinical Trials: Reliability and Prognostic Value of the Patient-Ranked Order of Function
Ruben P A van Eijk, Leonard H van den Berg, Ying Lu
Current Opinion in Neurology
|
August 16, 2020
Current trends in the clinical trial landscape for amyotrophic lateral sclerosis
Ruben P A van Eijk, Tessa Kliest, Leonard H van den Berg
Page
of 15
Search research articles
Search
Showing results (1-10 of 146) with videos related to
Sort By:
Page
of 15
Annals of Clinical and Translational Neurology
|
September 18, 2020
Frequent self-assessments in ALS Clinical Trials: worthwhile or an unnecessary burden for patients?
Ruben P A van Eijk
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
October 31, 2019
The rise of innovative clinical trial designs: what's in it for amyotrophic lateral sclerosis?
Ruben P A van Eijk, Angela Genge
Neurology
|
January 24, 2025
Author Response: Trial Participation in Neurodegenerative Diseases: Barriers and Facilitators: A Systematic Review and Meta-Analysis
Daphne N Weemering, Ruben P A van Eijk
Neurology
|
January 24, 2025
Author Response: Trial Participation in Neurodegenerative Diseases: Barriers and Facilitators: A Systematic Review and Meta-Analysis
Daphne N Weemering, Ruben P A van Eijk
Neurology
|
January 24, 2016
Comment: Plateaus and reversals in ALS disease course or limitations of trial design?
Ruben P A van Eijk, Leonard H van den Berg
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
October 12, 2019
In pursuit of the normal progressor: the holy grail for ALS clinical trial design?
Ruben P A van Eijk, Leonard H van Den Berg
Brain : a Journal of Neurology
|
December 10, 2024
Rethinking phase 2 trials in amyotrophic lateral sclerosis
Michael Benatar, Christopher McDermott, Martin R Turner, et al.
Brain : a Journal of Neurology
|
February 5, 2025
Reply: Overstating harms can have consequences
Michael Benatar, Christopher McDermott, Martin R Turner, et al.
Neurology
|
June 14, 2024
Cultivating Patient Preferences in ALS Clinical Trials: Reliability and Prognostic Value of the Patient-Ranked Order of Function
Ruben P A van Eijk, Leonard H van den Berg, Ying Lu
Current Opinion in Neurology
|
August 16, 2020
Current trends in the clinical trial landscape for amyotrophic lateral sclerosis
Ruben P A van Eijk, Tessa Kliest, Leonard H van den Berg
Page
of 15